Silvana Saracchini

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis et al. · The Lancet Oncology · 2018 · 88 citations · Full text

Medicine, Endocrinology, Oncology +11

Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer

Roberto Sorio, I. Robieux, Enzo Galligioni et al. · European Journal of Cancer · 1997 · 79 citations

Medicine, Pharmacokinetics, Pharmacology +14

Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study

Marina Elena Cazzaniga, G. Pinotti, Emilia Montagna et al. · The Breast · 2019 · 57 citations

Medicine, Oncology, Breast Oncology +9

Final overall survival results and effect of prolonged (≥1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial

Ian Smith, Jean‐Yves Pierga, Laura Biganzoli et al. · Breast Cancer Research and Treatment · 2011 · 51 citations

Medicine, Oncology, Breast Oncology +13

Treatment response in metastatic breast cancer. A multicentre study comparing UICC criteria and tumour marker changes

A. van Dalen, K J Heering, Vivian Barak et al. · The Breast · 1996 · 43 citations · Full text

Medicine, Oncology, Breast Oncology +16